Key facts
- This page summarizes Willie A. Deese's Form 4 filing for G1 Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2022, 16:51.
Willie A. Deese - 23 Jun 2022 Form 4 Insider Report for G1 Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 23 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2022, 16:51:19 UTC
- Prior SEC filing
- 25 May 2022
- Next SEC filing
- 06 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Stillman Hanson, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Willie A. Deese filed Form 4 for G1 Therapeutics, Inc. on 24 Jun 2022.
Change
- Previous filing in this sequence was filed on 25 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GTHX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +228%
- Price
- $0.000000
- Shares after
- 14,389
- Date
- 23 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GTHX
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 23 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $5.30
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director.
Footnote F2
Each RSU represents a contingent right to receive one share of Issuer common stock
Footnote F3
Represents 4,389 shares of common stock and 10,000 restricted stock units
Footnote F4
The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director.